Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

by Seini Moimoi | Nov 12, 2024 | Portfolio News

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

by Seini Moimoi | Nov 12, 2024 | Portfolio News

Bolt Medical Announces Completion of The RESTORE ATK and RESTORE BTK Pivotal Studies Investigating the Unique Bolt Intravascular Lithotripsy System

by Seini Moimoi | Nov 4, 2024 | Portfolio News

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

by Seini Moimoi | Oct 26, 2024 | Portfolio News

Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals

by Seini Moimoi | Oct 23, 2024 | Portfolio News

« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2025 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer